share_log

Organicell Regenerative Medicine Announces Expansion Into Health And Beauty Market

Organicell Regenerative Medicine Announces Expansion Into Health And Beauty Market

Organicell再生医学公司宣布进军保健和美容市场
Benzinga Real-time News ·  2022/09/16 08:48

MIAMI, FL / ACCESSWIRE / September 16, 2022 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company focused on the development of innovative biological therapeutics and regenerative medicine, announced today that the Company will expand into the skincare and haircare industries.

佛罗里达州迈阿密/ACCESSWIRE/2022年9月16日/致力于开发创新生物疗法和再生医学的临床阶段生物制药公司Organicell Regenerative Medicine,Inc.(OTCQB:OCEL)今天宣布,该公司将扩展到护肤和护发行业。

On September 14, 2022 BeautyHealth's Hydrafacial (NASDAQ:SKIN) announced its new partnership with Organicell to create the first to market exosome booster for their patented Hydrafacial device. Organicell's science team will work with Hydrafacial to prove the efficacy of how this new booster application may reduce inflammation, increase collagen, and increase elastin while extending the benefits of a traditional Hydrafacial.

2022年9月14日,美容美容(纳斯达克:Skin)宣布与Organicell建立新的合作伙伴关系,为其专利水润面部设备创造首个上市外体助推器。Organicell的科学团队将与HydraFacial合作,证明这种新的助推剂应用程序如何在延长传统HydraFacial的好处的同时,减少炎症、增加胶原蛋白和增加弹性蛋白的有效性。

Organicell's CEO, Matt Sinnreich, said "This partnership is the first of many we are working on in the aesthetic and hair space. Hydrafacial is its own market, and we have given them exclusivity for their applications, however, this partnership paves the way for our science team to start collecting data that may help prove the efficacy of our products on hair restoration and in various topical skincare and aftercare products.

Organicell的首席执行官Matt Sinnreich说:“这项合作是我们在美容和美发领域开展的众多合作项目中的第一项。Hydrafacial是它自己的市场,我们为它们的应用提供了独家经营权,然而,这一合作关系为我们的科学团队开始收集数据铺平了道路,这些数据可能有助于证明我们的产品在头发修复以及各种局部护肤和后期护理产品中的有效性。

"Extracellular Vesicles (EVs) are anti-inflammatory in nature. Our patent pending process allows us to concentrate up to 600 billion EVs per milliliter which contain over 300 cytokines, chemokines and growth factors. Organicell's science team will be researching how certain characterizations of our extracellular vesicles may be able to be used in hair transplant procedures to expedite healing and reduce swelling. They will be looking into how our products can possibly take the place of a Platelet-Rich Plasma (PRP) procedure for hair restoration. And our clinical research team will gather data to see how our EVs may help reduce wrinkles and the early signs of aging."

细胞外小泡(EVS)本质上是抗炎的。我们的专利申请过程允许我们每毫升浓缩高达6000亿个EVS,其中包含300多种细胞因子、趋化因子和生长因子。Organicell的科学团队将研究我们细胞外小泡的某些特征如何能够用于头发移植程序,以加快愈合和减少肿胀。他们将研究我们的产品如何可能取代富血小板血浆(PRP)程序来修复头发。我们的临床研究团队将收集数据,看看我们的EV如何帮助减少皱纹和衰老的早期迹象。

Sinnreich concluded, "This partnership is a great first step into the skincare space. We are honored that Hydrafacial trusted our science team enough to be their partner in this innovative new booster for their incredibly successful business. Now that the door is open, we can conduct the necessary research to prove our thesis on the rest of the applications which we believe the skincare and haircare market needs."

Sinnreich总结道:“这项合作是进入护肤领域的第一步。我们很荣幸HydraFacial能够充分信任我们的科学团队,成为他们在这项创新的新业务中的合作伙伴。现在大门已经打开,我们可以进行必要的研究,以证明我们在护肤和护发市场需要的其余应用上的论点。”

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发